ClinicalTrials.gg
Enrolling by invitationNCT05827601ZOOISUpdated Sep 8, 2023

Zoonotic Influenza Surveillance in Belgium

An observational study in Influenza, Human, sponsored by Cyril Barbezange. Enrolling by invitation at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-08.

Sponsored by Cyril Barbezange · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 106 studies in Influenza, Human with a site in Belgium — 4 open to participants now, 5 under way, 2 of them phase 3. Influenza, Human · Belgium.

Started
2023
with 2 others
Observational
9 of 106
2 open now
Registered
97th of 106
by date

Among the 106 studies in Influenza, Human with a site in Belgium, this one is one of 3 that started in 2023, is one of 9 observational ones, and was the 97th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 106 studies in Influenza, Human with a site in Belgium are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Influenza, Human with a site in Belgium, or all of them as a file.
02

Study summary

The project aims at implementing a more pro-active surveillance of potential transmission of influenza viruses to humans (zoonotic transmission). Clinical surveillance of influenza in humans and avian species is well organized and has been operating for decades, but currently there is no pro-active systematic surveillance of potential transmission of animal (avian or swine) influenza viruses to humans, only follow-up of people showing clinical symptoms. People working with potentially infected animals have the highest risk. Moreover, they can represent the first steps in a pandemic: if the virus adapts to humans, infected workers could potentially spread the virus to other people.

Currently, highly pathogenic clade2.3.4.4b H5 avian influenza viruses are continuously circulating in wild birds in Belgium and the number of introduction in poultry farms has raised, increasing the contact opportunities with high viral concentrations. Several reports of suspected human infection have been made by different countries. In addition, the virus was detected in sick non-human mammals. The large circulation in wild birds thus represents an increase risk of spill-over to mammalian species, including humans, (by contact directly with wild birds, or via outbreaks in poultry). This increased opportunity for accidental spillover to new host species increases the chances for the avian virus to adapt to mammals, including humans.

Likewise, there have also been an increased number of human cases of swine influenza reported by several European countries. A pro-active surveillance aiming at also detecting asymptomatic infections would allow an early detection of transmission that could help to prevent a new pandemic.

As a piloting approach during this specific project, some dedicated sentinel networks among at-risk workers will be initiated: people in poultry farms involved with the management of outbreaks of highly pathogenic avian influenza; people working at bird (or more generally wild life) rehabilitation centres or poultry farms; veterinarians working in pig farms/slaughterhouses.

03

Conditions studied

  • Influenza, Human

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Workers or volunteers of one of the targeted groups within the sites that accept to take part in the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • worker or volunteer of one of the targeted groups at one of the selected sites and accepting to take part in the study
  • to have regular contacts with animals within job/activity framework
  • being committed to take the regular samples

Exclusion criteria

Exclusion Criteria:

  • people who had a broken nose might have difficulties to perform self-swabbing
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Avian Influenza Outbreak Farms

    People involved in outbreak management, ranging from poultry farm owners and their family to inspectors through veterinarians and cullers/cleaners, will be invited to take part in the study at the earliest step possible after outbreak detection. Self sampling by nasopharyngeal swab will be requested every 2 days during 2 weeks.

    Diagnostic Test: respiratory specimen · Diagnostic Test: serum

  • Poultry Farm Sentinel Network

    People working in poultry farms and in contact with animals will be invited to join the cohort. Self sampling by nasopharyngeal swab will be requested every 2 weeks for the whole duration of the study. anticipated: 15

    Diagnostic Test: respiratory specimen

  • Wild bird/life Rehabilitation Centre Sentinel Network

    People working in wild bird/life rehabilitation centers and in contact with animals will be invited to join the cohort. Self sampling by nasopharyngeal swab will be requested every 2 weeks for the whole duration of the study. anticipated: 25

    Diagnostic Test: respiratory specimen

  • Pig Industry Veterinarian Sentinel Network

    Veterinarians working in the pig industry and in contact with animals will be invited to join the cohort. Self sampling by nasopharyngeal swab will be requested every 2 weeks for the whole duration of the study. anticipated: 15

    Diagnostic Test: respiratory specimen

Interventions

  • Diagnostic testrespiratory specimen

    participants will perform self-sampling with a nasopharyngeal swab

  • Diagnostic testserum

    participants will be invited to get a blood sample taken by a general practitioner or to perform a self sampling of capillary blood

06

What researchers measure

Primary outcomes

  1. Number of sentinel participants positive for a non-seasonal influenza virus

    result of RT-qPCR test to detect and characterize non-influenza viruses

    Time frame: every 2 weeks through study completion (December 2024)

  2. Number of outbreak participants positive for a non-seasonal influenza virus

    result of RT-qPCR test to detect and characterize non-influenza viruses

    Time frame: every 2 days during 2 weeks after enrollment

Secondary outcomes

  1. Number of outbreak participants with seroconversion against a non-seasonal influenza virus

    result of inhibition of haemagglutination or seroneutralisation assay

    Time frame: at enrollment and about 4 weeks after

07

Study locations

1 site
  • Sciensano
    Brussels, Belgium
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2024, 15 months after the start.

Of 98 non-industry observational studies under Influenza, Human, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 92. This study's planned 15 months is below that.

Counting every sponsor, half of 135 studies reached it within 23 months; a quarter within 7 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2023
First posted
Apr 25, 2023
StartActual
Sep 1, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Sep 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05827601
Lead sponsor
Cyril Barbezange
Collaborators
Sciensano, Belgian Federal Public Service, Food Chain Safety and Environment, Agentschap Zorg en Gezondheid
Responsible party
Cyril Barbezange (Head of Belgian National Influenza Centre, Sciensano) — Sponsor-investigator
First posted
Apr 25, 2023
Start date
Sep 1, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Sep 8, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion